Ritlecitinib
- Generic Name
- Ritlecitinib
- Brand Names
- Litfulo
- Drug Type
- Small Molecule
- Chemical Formula
- C15H19N5O
- CAS Number
- 1792180-81-4
- Unique Ingredient Identifier
- 2OYE00PC25
- Background
Ritlecitinib (PF-06651600) is a highly selective inhibitor of Janus kinase 3 (JAK3) and the tyrosine kinase expressed in hepatocellular carcinoma (TEC) kinase family. In June 2023, it was approved by the FDA for the treatment of severe alopecia areata in adults and adolescents 12 years and older. It was further approved by the EMA in September 2023. Ritlecit...
- Indication
Ritlecitinib is indicated for the treatment of severe alopecia areata in adults and adolescents 12 years and older. It is not recommended for use in combination with other JAK inhibitors, biologic immunomodulators, cyclosporine or other potent immunosuppressants.
- Associated Conditions
- Severe Alopecia Areata (AA)
- Associated Therapies
- -
Efficacy and Safety of JAK Inhibitors in Patients With AA: RWE Study
- First Posted Date
- 2024-08-27
- Last Posted Date
- 2024-08-27
- Target Recruit Count
- 150
- Registration Number
- NCT06573593
- Locations
- 🇨🇳
Second Affiliated Hospital, School of Medicine, Zhejiang University, China, Hangzhou, Zhejiang, China
Characterization And Clinical Outcomes of AA Patients Treated With Ritlecitinib
- First Posted Date
- 2024-07-31
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 850
- Registration Number
- NCT06531109
- Locations
- 🇺🇸
Cura Clinical Research, Oxnard, California, United States
🇺🇸Pediatric Skin Research,LLC, Coral Gables, Florida, United States
🇺🇸Suncoast Skin Solutions, Jacksonville, Florida, United States
Ritlecitinib in Patients With Keloids or Those Undergoing Keloidectomy
- First Posted Date
- 2024-04-18
- Last Posted Date
- 2024-09-30
- Lead Sponsor
- Icahn School of Medicine at Mount Sinai
- Target Recruit Count
- 30
- Registration Number
- NCT06373458
- Locations
- 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States
A Study to Learn About How Different Forms of the Study Medicine Called Ritlecitinib Pass the Intestines of Healthy Male Adults When Taken With or Without Food
- First Posted Date
- 2024-04-17
- Last Posted Date
- 2024-08-28
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 12
- Registration Number
- NCT06369454
- Locations
- 🇺🇸
Scintipharma - Lexington - Maywick View Lane, Lexington, Kentucky, United States
A Study to Learn About Three Forms of The Study Medicine (Ritlecitinib) in Healthy Adults
- First Posted Date
- 2023-12-15
- Last Posted Date
- 2024-04-04
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 12
- Registration Number
- NCT06172348
- Locations
- 🇧🇪
Pfizer Clinical Research Unit - Brussels, Brussels, Bruxelles-capitale, Région DE, Belgium
A 52-Week Study to Learn About the Safety and Effects of Ritlecitinib in Participants With Nonsegmental Vitiligo
- Conditions
- Interventions
- First Posted Date
- 2023-12-08
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 400
- Registration Number
- NCT06163326
- Locations
- 🇺🇸
University of New Mexico Health Sciences Center, Albuquerque, New Mexico, United States
🇺🇸Alpesh D. Desai, DO PLLC, Houston, Texas, United States
🇯🇵Nagoya City University Hospital, Nagoya, Aichi, Japan
A 104-Week Study of Ritlecitinib Oral Capsules in Adults With Nonsegmental Vitiligo (Active and Stable) Tranquillo 2
- Conditions
- Interventions
- First Posted Date
- 2023-10-10
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1450
- Registration Number
- NCT06072183
- Locations
- 🇺🇸
FXM Clinical Research - Miramar, Miramar, Florida, United States
🇺🇸GCP Research, Global Clinical professionals, Saint Petersburg, Florida, United States
🇺🇸USF Health, Tampa, Florida, United States
Ritlecitinib in CTCL
- First Posted Date
- 2023-05-30
- Last Posted Date
- 2024-05-07
- Lead Sponsor
- Icahn School of Medicine at Mount Sinai
- Target Recruit Count
- 20
- Registration Number
- NCT05879458
- Locations
- 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States
A Study to Assess Two Forms of The Study Medicine (Ritlecitinib) in Healthy Adult Participants
- First Posted Date
- 2023-05-10
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 12
- Registration Number
- NCT05852340
- Locations
- 🇧🇪
Pfizer Clinical Research Unit - Brussels, Brussels, Bruxelles-capitale, Région DE, Belgium
Janus Kinase (JAK) Inhibitors to Preserve C-Peptide Production in New Onset Type 1 Diabetes (T1D)
- Conditions
- Interventions
- First Posted Date
- 2023-02-24
- Last Posted Date
- 2024-10-21
- Target Recruit Count
- 78
- Registration Number
- NCT05743244
- Locations
- 🇺🇸
Children's Hospital Orange County, Orange, California, United States
🇺🇸Stanford University, Palo Alto, California, United States
🇺🇸University of California- San Francisco, San Francisco, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.